Atreca, Genome Institute of Singapore Collaborate
Complete the form below to unlock access to ALL audio articles.
Atreca, Inc., and the Genome Institute of Singapore (GIS), have entered into a research collaboration agreement to advance Atreca’s high-throughput, microfluidic technology for single-cell, sequence-based analyses of human immune responses, critical in the discovery and development of immuno-oncology therapeutics.
Co-funded by A*STAR and Atreca, and involving Atreca’s Singapore subsidiary, Atreca Pte. Ltd., this research effort will establish a joint lab at the GIS facility in Singapore’s Biopolis campus to add new capabilities to Atreca’s microfluidic technology for next-generation sequence analysis of expressed genes in single cells. These capabilities will include identification of genes for immunoglobulin superfamily members, such as antibodies and T cell receptors (TCRs), as well as other genes in B and T cells that play important roles in directing the body’s immune response towards cancer and pathogens, such as bacteria and viruses. The ability to analyse these genes is expected to pave the way for more targeted and effective immunotherapies. Tan Yann Chong, Ph.D., Co-Founder of Atreca, Inc., and an A*STAR scholar, will head the Atreca-GIS Joint Laboratory.
“This collaboration with GIS will facilitate advancing our state-of-the-art technology for analysing human and model system immune responses, a capability that is central to Atreca’s therapeutic focus in immuno-oncology,” commented Tito A. Serafini, Ph.D., Atreca’s President, Chief Executive Officer, and Co-Founder. “GIS offers a world-class research environment, bringing together leading expertise in next-generation sequencing, molecular cytogenetics, bioinformatics, and single cell genomics, and we are delighted to work with them on this effort.”
Prof. Ng Huck Hui, Executive Director of GIS, stated, “We welcome the opportunity to partner with Atreca. This will see significant advancements in our research, including in precision medicine and infectious diseases, and further our collaborative work with the clinical community to offer therapeutic answers directly to patients.”
Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
